Cargando…
A novel substitution in NS5A enhances the resistance of hepatitis C virus genotype 3 to daclatasvir
Hepatitis C virus (HCV) genotype 3 presents a high level of both baseline and acquired resistance to direct-acting antivirals (DAAs), particularly those targeting the NS5A protein. To understand this resistance we studied a cohort of Brazilian patients treated with the NS5A DAA, daclatasvir and the...
Autores principales: | Fernandes Campos, Guilherme Rodrigues, Ward, Joseph, Chen, Shucheng, Bittar, Cintia, Vilela Rodrigues, João Paulo, Martinelli, Ana de Lourdes Candolo, Souza, Fernanda Fernandes, Pereira, Leonardo Régis Leira, Rahal, Paula, Harris, Mark |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Microbiology Society
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8116786/ https://www.ncbi.nlm.nih.gov/pubmed/33141008 http://dx.doi.org/10.1099/jgv.0.001496 |
Ejemplares similares
-
Corrigendum: A novel substitution in NS5A enhances resistance of hepatitis C virus genotype 3 to daclatasvir
por: Fernandes Campos, Guilherme Rodrigues, et al.
Publicado: (2021) -
Selection dynamics of HCV genotype 3 resistance-associated substitutions under direct-acting antiviral therapy pressure
por: Rodrigues, João Paulo Vilela, et al.
Publicado: (2022) -
NS5A Sequence Heterogeneity and Mechanisms of Daclatasvir Resistance in Hepatitis C Virus Genotype 4 Infection
por: Zhou, Nannan, et al.
Publicado: (2016) -
New insights regarding HCV-NS5A structure/function and indication of genotypic differences
por: Yamasaki, Lilian HT, et al.
Publicado: (2012) -
Evaluation of Resistance-Associated Substitutions in NS5A Using Direct Sequence and Cycleave Method and Treatment Outcome with Daclatasvir and Asunaprevir for Chronic Hepatitis C Genotype 1
por: Ide, Tatsuya, et al.
Publicado: (2016)